Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK

Penn, Linda; White, Martin; Oldroyd, John; Walker, Mark; Alberti, K George MM; Mathers, John C.
January 2009
BMC Public Health;2009, Vol. 9, p342
Academic Journal
Background: Diabetes prevalence is increasing. The Finnish Diabetes Prevention Study (DPS) showed a 58% reduction in Type 2 Diabetes (T2D) incidence in adults with impaired glucose tolerance (IGT). The European Diabetes Prevention Study (EDIPS) extends the DPS to different European populations, using the same study design. In the Newcastle arm of this study (EDIPS-Newcastle), we tested the hypothesis that T2D can be prevented by lifestyle intervention and explored secondary outcomes in relation to diabetes incidence. Methods: We recruited 102 participants (42 men and 60 women, mean age 57 years, mean BMI 34 kgm-2) with IGT to EDIPS-Newcastle and randomised to Intervention and usual care Control groups. The intervention included individual motivational interviewing aimed at: weight reduction, increase in physical activity, fibre and carbohydrate intake and reduction of fat intake (secondary outcomes). The primary outcome was diagnosis of T2D. Results: Mean duration of follow-up was 3.1 years. T2D was diagnosed in 16 participants (I = 5, C = 11). Absolute incidence of T2D was 32.7 per 1000 person-years in the Intervention-group and 67.1 per 1000 person-years in the Control-group. The overall incidence of diabetes was reduced by 55% in the Intervention-group, compared with the Control-group: RR 0.45 (95%CI 0.2 to 1.2). Explanatory survival analysis of secondary outcomes showed that those who sustained beneficial changes for two or more years reduced their risk of developing T2D. Conclusion: Our results are consistent with other diabetes prevention trials. This study was designed as part of a larger study and although the sample size limits statistical significance, the results contribute to the evidence that T2D can be prevented by lifestyle changes in adults with IGT. In explanatory analysis small sustained beneficial changes in weight, physical activity or dietary factors were associated with reduction in T2D incidence. Trial Registration: International Standard Randomised Controlled Trial Number registry (ISRCTN) Registry number: ISRCTN 15670600


Related Articles

  • Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. Kaushal, Shaveta; Singh, Harmanjit; Thangaraju, Pugazhenthan; Singh, Jasbir // North American Journal of Medical Sciences;Mar2014, Vol. 6 Issue 3, p107 

    Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs...

  • INCRETIN DRUGS FOR TYPE 2 DIABETES. Kenny, Colin // Pulse;12/17/2008, Vol. 68 Issue 44, p30 

    The article presents pointers in treating type 2 diabetes. The incretin effect refers to the hormones produced by the gastrointestinal (GI) tract in response to eating. It notes that exenatide slows gastric emptying and promotes satiety centrally. These mechanisms are connected with diminished...

  • Physical activity and type 2 diabetes mellitus.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Mar2012, Vol. 17 Issue 1, pS18 

    The article presents findings of studies conducted on examining the affect of physical activity in the treatment and prevention of type 2 diabetes mellitus. It mentions that regular physical activity significantly improves glycaemic control and reduces cardiovascular risk factors in patients...

  • Intensified treatment with insulin detemir improved glycemic control, weight loss.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p20 

    The article reports that a randomized trial has found that adding insulin detemir to a treatment regimen of metformin and liraglutide resulted to improved glycemic control and sustained weight loss for up to 52 weeks in patients with type 2 diabetes.

  • Can 15 LB reverse diabetes? Davis, James; R.M.D. // Cortlandt Forum;11/25/95, Vol. 8 Issue 11, p87 

    Answers the question on studies proving that small weight loss can reverse adult-onset diabetes mellitus. Indication of the little effect of a small amount of weight loss.

  • Insulin-based therapies in type 2 diabetes.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Mar2012, Vol. 17 Issue 1, pS32 

    The article presents several studies conducted on examining the insulin-based therapies in type 2 diabetes. One study reveals that patients with type 2 diabetes assigned to receive a basal, biphasic or prandial insulin regimen, the mean glycated haemoglobin levels at one year were similar in the...

  • The 2012 SEMDSA Treatment Algorithm for Type 2 Diabetes.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Mar2012, Vol. 17 Issue 1, pS36 

    Several tables are presented discussing 2012 Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) Treatment Algorithm for type 2 diabetes including one on antihyperglycaemic agents used in type 2 diabetes and antihyperglycaemic agents used in type 2 diabetes.

  • Should GPs lower HbA1c targets? Moberly, Tom // GP: General Practitioner;5/7/2010, p26 

    The article focuses on the debate that whether hemoglobin A1c (HbA1c) targets should be lowered or not in patients with type-2 diabetes. It states that action to control cardiovascular risk in diabetes (ACCORD) study published in the 2010 issue of the periodical "Diabetes Care" reveals that...

  • The antidiabetic gutsy role of metformin uncovered? Burcelin, Rémy // Gut;May2014, Vol. 63 Issue 5, p706 

    The author comments on the research study concerning on the medical role of metformin as treatment for lowering hyperglycaemia in type 2 diabetic patients. He mentions the antidiabetic effect of metformin abrogated by an antibiotic treatment reinforcing the significant of gut microbiota. He also...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics